Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 4/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745021 | 0.84 | CCR1 (0.38) | ACVR1JAK3PTK2 | |
| SCHEMBL20598022 | 0.84 | CCR1 (0.38) | ACVR1JAK3PTK2 | |
| SCHEMBL19092140 | 0.79 | CYP17A1 (0.33) | CYP17A1CYP1A2 | |
| SCHEMBL19092433 | 0.78 | KHK (0.46) | ACVR1BMPR1BBMPR1AACVR1BACVRL1 | |
| SCHEMBL20598011 | 0.69 | GPR119 (0.45) | RETJAK2JAK3PTK2 | |
| SCHEMBL26026399 | 0.62 | SCN9A (0.33) | CYP17A1CYP1A2 | |
| SCHEMBL19092141 | 0.61 | HTR2A (0.41) | — | |
| SCHEMBL20598131 | 0.60 | USP5 (0.44) | — | |
| SCHEMBL30716966 | 0.59 | CYP1A2 (0.61) | CYP17A1CYP1A2 | |
| SCHEMBL26970884 | 0.59 | CYP1A2 (0.61) | CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| WO-2018059549-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |